{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:38:54Z","timestamp":1792035534326,"version":"4.4.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH001"],"award-info":[{"award-number":["ZR2023QH001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024YQ053"],"award-info":[{"award-number":["ZR2024YQ053"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","award":["2020QNQT003"],"award-info":[{"award-number":["2020QNQT003"]}],"id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["825B2115"],"award-info":[{"award-number":["825B2115"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425056"],"award-info":[{"award-number":["82425056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303171"],"award-info":[{"award-number":["82303171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350125"],"award-info":[{"award-number":["82350125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.115012","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:51:36Z","timestamp":1778547096000},"page":"115012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Engineering immune cells for next-generation therapies"],"prefix":"10.1016","volume":"395","author":[{"given":"Maosen","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhao","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengkai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115012_bb0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41587-025-02629-5","article-title":"Engineering innate immune cells for cancer immunotherapy","volume":"43","author":"Tarannum","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0020","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.jconrel.2026.115012_bb0030","doi-asserted-by":"crossref","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0035","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2026.115012_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0060","article-title":"CAR-NK cells for cancer immunotherapy: recent advances and future directions","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114379","article-title":"In vivo nano-engineering T cells for CAR-T therapy","volume":"388","author":"Shi","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115012_bb0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.115012_bb0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"10.1016\/j.jconrel.2026.115012_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/v13081528","article-title":"Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives","volume":"13","author":"Labb\u00e9","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2026.115012_bb0085","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0090","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-023-01680-5","article-title":"Programmable synthetic receptors: the next-generation of cell and gene therapies","volume":"9","author":"Teng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2014.00232","article-title":"The activity of Nef on HIV-1 infectivity","volume":"5","author":"Basmaciogullari","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0110","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1128\/JVI.76.10.4950-4960.2002","article-title":"cis-acting elements important for retroviral RNA packaging specificity","volume":"76","author":"Beasley","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0115","doi-asserted-by":"crossref","first-page":"7791","DOI":"10.1073\/pnas.96.14.7791","article-title":"Recruitment of cyclin T1\/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription","volume":"96","author":"Bieniasz","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2026.115012_bb0120","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0125","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/v13050735","article-title":"HIV-1 entry and membrane fusion inhibitors","volume":"13","author":"Xiao","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2026.115012_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2017.098","article-title":"Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice","volume":"29","author":"G\u00e1ndara","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.jconrel.2026.115012_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0140","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: the first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.09.004","article-title":"Construction and application of adenoviral vectors","volume":"34","author":"Zhang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115012_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115012_bb0160","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti\u2013Zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0165","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0170","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2217\/fvl.13.112","article-title":"Adeno-associated virus structural biology as a tool in vector development","volume":"8","author":"Drouin","year":"2013","journal-title":"Future Virol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0180","doi-asserted-by":"crossref","first-page":"9878","DOI":"10.1128\/JVI.01568-16","article-title":"Heparan sulfate binding promotes accumulation of intravitreally delivered adeno-associated viral vectors at the retina for enhanced transduction but weakly influences tropism","volume":"90","author":"Woodard","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0185","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0190","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2026.115012_bb0195","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0200","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1038\/s41467-023-42386-0","article-title":"mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy","volume":"14","author":"Riedmayr","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115012_bb0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/hum.2019.220","article-title":"Can adeno-associated viral vectors deliver effectively large genes?","volume":"31","author":"Tornabene","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0210","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115012_bb0215","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0220","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","article-title":"In Vivo Base editing rescues Hutchinson-Gilford progeria syndrome in mice","volume":"589","author":"Koblan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115012_bb0225","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0230","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jconrel.2026.115012_bb0240","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0245","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/jcm10051044","article-title":"RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates","volume":"10","author":"Huber","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0250","first-page":"1","article-title":"Directed evolution of engineered virus-like particles with improved production and transduction efficiencies","author":"Raguram","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0255","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41467-023-40788-8","article-title":"Cell type-specific delivery by modular envelope design","volume":"14","author":"Strebinger","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115012_bb0260","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0265","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2025.100011","article-title":"Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells","volume":"1","author":"Wang","year":"2025","journal-title":"Cell Biomater."},{"key":"10.1016\/j.jconrel.2026.115012_bb0275","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.115012_bb0280","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-023-02044-5","article-title":"Emerging non-viral vectors for gene delivery","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0285","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","article-title":"Non-viral vectors for RNA delivery","volume":"342","author":"Yan","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115012_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120375","article-title":"Gene therapy: comprehensive overview and therapeutic applications","volume":"294","author":"Sayed","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2026.115012_bb0295","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0300","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0305","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115012_bb0310","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.115012_bb0315","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115012_bb0320","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb0330","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115012_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1598","article-title":"Polymer-mediated gene therapy: recent advances and merging of delivery techniques","volume":"12","author":"Salameh","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0340","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/polym16182629","article-title":"Polymers as efficient non-viral gene delivery vectors: the role of the chemical and physical architecture of macromolecules","volume":"16","author":"Khan","year":"2024","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115012_bb0345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.addr.2020.06.014","article-title":"Polymeric vehicles for nucleic acid delivery","volume":"156","author":"Piotrowski-Daspit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115012_bb0350","first-page":"59","article-title":"Synthetic approaches for nucleic acid delivery: choosing the right carriers","volume":"9","author":"Ni","year":"2019","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jconrel.2026.115012_bb0355","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0360","article-title":"Injectable supramolecular hydrogels for in situ programming of CAR-T cells toward solid tumor immunotherapy","volume":"36","author":"Zhu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115012_bb0365","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","article-title":"In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles","volume":"69","author":"Zhao","year":"2024","journal-title":"Sci. Bull."},{"key":"10.1016\/j.jconrel.2026.115012_bb0370","doi-asserted-by":"crossref","first-page":"eadg3365","DOI":"10.1126\/sciadv.adg3365","article-title":"Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115012_bb0375","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0380","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0385","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","article-title":"Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy","volume":"40","author":"Dabas","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0390","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0395","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0400","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci."},{"key":"10.1016\/j.jconrel.2026.115012_bb0405","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0410","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115012_bb0415","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0420","doi-asserted-by":"crossref","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0430","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2026.115012_bb0440","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1273302","article-title":"CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy","volume":"6","author":"Chen","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115012_bb0445","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1038\/s41467-022-31141-6","article-title":"Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-\u03b2 degradation","volume":"13","author":"Shen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115012_bb0450","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","article-title":"Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal","volume":"33","author":"Zheng","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0455","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115012_bb0460","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191166","article-title":"A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy","volume":"217","author":"Oda","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0465","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1126\/science.abc6270","article-title":"Precise T cell recognition programs designed by transcriptionally linking multiple receptors","volume":"370","author":"Williams","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb0470","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4237","article-title":"Programming tissue-sensing T cells that deliver therapies to the brain","volume":"386","author":"Simic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb0475","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0480","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0485","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0490","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-023-03368-2","article-title":"CAR-T cell therapy: a game-changer in cancer treatment and beyond","author":"Utkarsh","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0495","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.115012_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0505","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/d41586-024-03209-4","article-title":"World-first therapy using donor cells sends autoimmune diseases into remission","volume":"634","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115012_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457629","article-title":"Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy","volume":"15","author":"Fang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0515","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1165576","article-title":"Biomaterials promote in vivo generation and immunotherapy of CAR-T cells","volume":"14","author":"Qin","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0525","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.omtm.2018.10.006","article-title":"Surface-engineered lentiviral vectors for selective gene transfer into subtypes of lymphocytes","volume":"12","author":"Frank","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.115012_bb0530","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.115012_bb0535","series-title":"T Cells: The Usual Subsets","author":"Dong","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115012_bb0540","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","article-title":"Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity","volume":"15","author":"Yan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0545","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","article-title":"Principles and therapeutic applications of adaptive immunity","volume":"187","author":"Chi","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0550","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcp.10290","article-title":"MHC class I antigens, immune surveillance, and tumor immune escape","volume":"195","author":"Garcia-Lora","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0555","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115012_bb0560","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115012_bb0565","article-title":"MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I\/IIa clinical trial","volume":"15","author":"Rohaan","year":"2022","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0570","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell receptors targeting KRAS-mutated human tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115012_bb0575","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115012_bb0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41587-024-02529-0","article-title":"A cure for HIV? TCR agents seek to wipe out viral reservoirs","volume":"43","author":"Hoyos-Flight","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0585","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3350\/cmh.2024.0058","article-title":"Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting","volume":"30","author":"Wan","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0590","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ni1001-962","article-title":"Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer","volume":"2","author":"Stanislawski","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149209","article-title":"How does TCR-T cell therapy exhibit a superior anti-tumor efficacy","volume":"687","author":"Yang","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115012_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.794183","article-title":"TCR-T immunotherapy: the challenges and solutions","volume":"11","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0605","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115012_bb0610","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.jconrel.2026.115012_bb0615","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0620","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0625","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0630","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-024-01100-5","article-title":"Novel strategies to manage CAR-T cell toxicity","author":"Mulvey","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115012_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: a new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0645","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s00018-011-0907-z","article-title":"The battle against immunopathology: infectious tolerance mediated by regulatory T cells","volume":"69","author":"Gravano","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2026.115012_bb0650","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb0655","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0660","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127\u2212 regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.115012_bb0665","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.115012_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0675","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jconrel.2026.115012_bb0680","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.115012_bb0685","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated Cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb0690","article-title":"CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions","volume":"3","author":"Abraham","year":"2023","journal-title":"Front. Ophthalmol. (Lausanne)"},{"key":"10.1016\/j.jconrel.2026.115012_bb0695","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10753-017-0704-4","article-title":"Adoptive induced antigen-specific treg cells reverse inflammation in collagen-induced arthritis mouse model","volume":"41","author":"Sun","year":"2018","journal-title":"Inflammation"},{"key":"10.1016\/j.jconrel.2026.115012_bb0700","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2026.115012_bb0705","first-page":"2256","article-title":"GPIb\u03b1 CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia","volume":"109","author":"Zhou","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2026.115012_bb0710","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: an in-vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.115012_bb0720","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcdb.2015.05.004","article-title":"Human mononuclear phagocyte system reunited","volume":"41","author":"Haniffa","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173090","article-title":"Macrophage M1\/M2 polarization","volume":"877","author":"Yunna","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0730","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0735","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115012_bb0740","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1172\/JCI31422","article-title":"Altered macrophage differentiation and immune dysfunction in tumor development","volume":"117","author":"Sica","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115012_bb0745","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","article-title":"Macrophages at the interface of the co-evolving cancer ecosystem","volume":"186","author":"Akkari","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0750","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","article-title":"Macrophages at the interface of the co-evolving cancer ecosystem","volume":"186","author":"Kloosterman","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: a new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2026.115012_bb0760","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1073\/pnas.92.11.5106","article-title":"Analysis of the interaction of ZAP-70 and syk protein-tyrosine kinases with the T-cell antigen receptor by plasmon resonance","volume":"92","author":"Bu","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2026.115012_bb0765","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2026.115012_bb0770","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0775","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0780","article-title":"Legumain in situ engineering promotes efferocytosis of CAR macrophage to treat cardiac fibrosis","author":"Liu","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115012_bb0785","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","article-title":"Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models","volume":"80","author":"Dai","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0790","article-title":"An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma","author":"Jing","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0795","article-title":"Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0800","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0805","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0810","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","article-title":"Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0815","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0820","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12943-024-02045-4","article-title":"Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications","volume":"23","author":"Si","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0825","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","article-title":"The natural cytotoxicity receptors in health and disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0830","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/icb.2013.98","article-title":"Natural cytotoxicity receptors and their ligands","volume":"92","author":"Kruse","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0835","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2326-6066.CIR-19-0404","article-title":"Harnessing natural killer cell antitumor immunity: from the bench to bedside","volume":"7","author":"Woan","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115012_bb0840","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","article-title":"Immunometabolism and natural killer cell responses","volume":"19","author":"O\u2019Brien","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0845","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115012_bb0850","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jconrel.2026.115012_bb0855","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115012_bb0860","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101073","article-title":"Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting","volume":"60","author":"Merino","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.jconrel.2026.115012_bb0870","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115012_bb0875","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0880","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb0885","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn0881","article-title":"CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer","volume":"10","author":"Tarannum","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115012_bb0890","article-title":"Enhancing CAR-NK cells against solid tumors through chemical and genetic fortification with DOTAP-functionalized lipid nanoparticles","volume":"34","author":"Shin","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.115012_bb0895","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0900","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","author":"Lei","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb0905","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/aps.2017.125","article-title":"Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy","volume":"39","author":"Hu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2026.115012_bb0910","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115012_bb0915","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41586-026-10149-8","article-title":"OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours","volume":"652","author":"Yang","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115012_bb0920","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev-immunol-101819-025146","article-title":"Dendritic cell regulation of T helper cells","volume":"39","author":"Yin","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0925","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb0930","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-024-03788-1","article-title":"Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy","volume":"73","author":"Duan","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.115012_bb0935","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb0940","article-title":"Engineered immunosuppressive dendritic cells protect against cardiac remodelling","author":"Li","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115012_bb0945","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115012_bb0950","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01656-0","article-title":"CAR-neutrophils produced in vivo to treat glioma","author":"Chang","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115012_bb0955","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41551-024-01195-6","article-title":"Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression","volume":"8","author":"Sirpilla","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115012_bb0960","doi-asserted-by":"crossref","first-page":"eads3972","DOI":"10.1126\/science.ads3972","article-title":"Targeting amyloid-\u03b2 pathology by chimeric antigen receptor astrocyte (CAR-A) therapy","volume":"391","author":"Chen","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb0965","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","article-title":"Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction","volume":"4","author":"Amor","year":"2024","journal-title":"Nat. Aging"},{"key":"10.1016\/j.jconrel.2026.115012_bb0970","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115012_bb0975","series-title":"Intraperitoneal Programming of Tailored CAR Macrophages via mRNA-LNP to Boost Cancer Immunotherapy","author":"Gu","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115012_bb0980","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1200\/JCO.2022.40.16_suppl.7567","article-title":"Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): outcomes of the phase 2 ZUMA-14 study","volume":"40","author":"Strati","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.jconrel.2026.115012_bb0985","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115012_bb0990","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1182\/blood-2023-184505","article-title":"Rituximab improves clinical outcomes of CAR-T therapy for r\/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115012_bb0995","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115012_bb1000","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb1005","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115012_bb1010","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb1015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298683","article-title":"Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors","volume":"14","author":"He","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb1020","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/07388551.2021.1988509","article-title":"Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic","volume":"42","author":"Safarzadeh Kozani","year":"2022","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb1025","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jconrel.2026.115012_bb1030","doi-asserted-by":"crossref","DOI":"10.1111\/imm.70124","article-title":"Strategies of AI-driven CAR-T cell therapy towards solid tumours","author":"Abdalla","year":"2026","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2026.115012_bb1035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41587-020-00793-4","article-title":"Deep diversification of an AAV capsid protein by machine learning","volume":"39","author":"Bryant","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb1040","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2174\/0113816128286593240226060318","article-title":"Machine-learning-guided directed evolution for AAV capsid engineering","volume":"30","author":"Fu","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2026.115012_bb1045","article-title":"High-throughput strategies for streamlining lipid nanoparticle development pipeline","volume":"12","author":"Lam","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.jconrel.2026.115012_bb1050","article-title":"Advancing cellular-specific delivery: machine learning insights into lipid nanoparticles design and cellular tropism","volume":"14","author":"Hanafy","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.115012_bb1055","doi-asserted-by":"crossref","first-page":"28735","DOI":"10.1021\/acsnano.4c07615","article-title":"Machine learning elucidates design features of plasmid deoxyribonucleic acid lipid nanoparticles for cell type-preferential transfection","volume":"18","author":"Cheng","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115012_bb1060","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41587-023-01686-y","article-title":"Single-cell mapping of combinatorial target antigens for CAR switches using logic gates","volume":"41","author":"Kwon","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115012_bb1065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137231","article-title":"Artificial intelligence-powered molecular docking and steered molecular dynamics for accurate scFv selection of anti-CD30 chimeric antigen receptors","volume":"25","author":"Martarelli","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115012_bb1070","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.ymthe.2025.07.044","article-title":"Computational structural optimization enhances IL13R\u03b12 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape","volume":"33","author":"Meehl","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115012_bb1075","article-title":"Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives","volume":"12","author":"Shahzadi","year":"2024","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"10.1016\/j.jconrel.2026.115012_bb1080","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1126\/science.abq0225","article-title":"Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning","volume":"378","author":"Daniels","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115012_bb1085","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2023.1250508","article-title":"Elaborating the potential of artificial intelligence in automated CAR-T cell manufacturing","volume":"3","author":"B\u00e4ckel","year":"2023","journal-title":"Front. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb1090","article-title":"CART-GPT: A T Cell-informed AI linguistic framework for interpreting neurotoxicity and therapeutic outcomes in CAR-T therapy","author":"Mao","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2026.115012_bb1095","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3343\/alm.2023.0382","article-title":"Manufacturing cell and gene therapies: challenges in clinical translation","volume":"44","author":"Lee","year":"2024","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.jconrel.2026.115012_bb1100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00281-024-01019-4","article-title":"Advances in manufacturing chimeric antigen receptor immune cell therapies","volume":"46","author":"Ramamurthy","year":"2024","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jconrel.2026.115012_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.115012_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101613","article-title":"From cold chain to ambient: benefits, risks, and evidence across cell therapy logistics","volume":"33","author":"Gostage","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.115012_bb1115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115012_bb1120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011698","article-title":"Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis","volume":"13","author":"Andreu-Sanz","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115012_bb1125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1656108","article-title":"Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review","volume":"16","author":"Ke","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115012_bb1130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/clinchem\/hvad179","article-title":"Emerging biomarkers for monitoring chimeric antigen receptor T-cell therapy","volume":"70","author":"Mamo","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jconrel.2026.115012_bb1135","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2024025828","article-title":"T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:25:35Z","timestamp":1783052735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":227,"alternative-id":["S0168365926004153"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering immune cells for next-generation therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115012"}}